Emerging Stocks Down Under 3 May 2022: Kazia Therapeutics (ASX:KZA)

Emerging Stocks Down Under 3 May 2022: Kazia Therapeutics (ASX:KZA) 2
Kazia Therapeutics: A biotech taking on brain cancer
Kazia Therapeutics is tackling brain cancer, which is one of the deadliest forms of cancer. It's lead asset Paxalisib has passed a Phase 2 and is currently in a Phase 3 study along with additional Phase 1 studies against other indications. We like this company for its cash reserves, the strong IP protection of its assets along with the work it has done to prepare for the drug's eventual commercialisation. Click here to read the previous edition of Emerging Stocks Down Under published 26 April 2022 For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.
Please register or upgrade your plan to access this content.

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 5 publications per week
Weekly Investor Webinar
Profit Premium
$69
Get access to 5 publications per week
Access to the full research Archive
Weekly Investor Webinar
30-Day Free Trial
$0
No Credit Card Required!
Get access to 5 publications per week
Weekly Investor Webinar
Profit Premium
$59
BILLED ANNUALLY
Get access to 5 publications per week
Access to the full research Archive
Weekly Investor Webinar